Skip to Main Content

Evaluating imported unlicensed medicines

Event 22 May 2026Location Online via Webex at 13:00 – 14:00
Topics: EventsPast Events

An SPS Quality Assurance (QA) bite size learning event on evaluating imported unlicensed medicines.

Date

22 May 2026

Location

Online via Webex at 13:00 – 14:00

About the event

This drop in session explored considerations for imported unlicensed medicines.

Why it’s important

Medicinal products supplied in the UK must have a UK marketing authorisation (product licence) except when there is a special clinical need that cannot be fulfilled by the use of a UK licensed medicine.

In these cases the use of unlicensed medicines can meet a patient’s clinical needs that would otherwise be unmet.

There are a range of different types of unlicensed medicines, and in this webinar we will explore considerations when sourcing and evaluating imported unlicensed medicines.

This session helped attendees by exploring:

  • regulatory and safety considerations
  • how to assess the quality and suitability of imported unlicensed medicines
  • good governance arrangements for safely managing this type of product

Intended audience

The session was suitable for NHS:

  • clinical pharmacy teams
  • pharmacy procurement teams
  • pharmacy quality assurance teams
  • dispensary teams
  • medicines advice teams

Register

Registration is now closed.

Video recording

Resources

The MHRA provides guidance on unlicensed medicinal products (specials).

NHS SPS guidance

Further useful NHS SPS resources are found here:

NHS Futures unlicensed medicines peer support network

An unlicensed medicines peer-support network is available to join on the Future NHS platform. It contains useful resources and a discussion forum, and provides a place to collaborate.

 

 

Update history

  1. Video recording added
  1. Published